Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 5-year average of 57.89%, near the high end of its 5-year range (-16136.36%–100.00%).
100.00% below its 12-month average of 20.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
20.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
57.89%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
43.48%
median of 452 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Allogene Therapeutics, Inc.
Market Cap
$517.73M
Gross Margin
0.00%
TTM Avg
20.00%
3Y Avg
0.00%
5Y Avg
57.89%
Market Cap
$517.79M
Gross Margin
100.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
83.33%
Market Cap
$519.25M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
31.77%
Market Cap
$491.55M
Gross Margin
42.92%
TTM Avg
41.39%
3Y Avg
40.24%
5Y Avg
40.24%
Market Cap
$547.86M
Gross Margin
87.05%
TTM Avg
84.77%
3Y Avg
78.39%
5Y Avg
75.97%
Market Cap
$487.30M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$551.09M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $517.73M | 0.00% | 20.00% | 0.00% | 57.89% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | 100.00% | 50.00% | 75.00% | 83.33% |
| Altimmune, Inc. (ALT)vs › | $519.25M | 100.00% | 100.00% | 100.00% | 31.77% |
| Evolus, Inc. (EOLS)vs › | $491.93M | 66.25% | 66.66% | 65.82% | 64.54% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | 42.92% | 41.39% | 40.24% | 40.24% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 87.05% | 84.77% | 78.39% | 75.97% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | 0.00% | 0.00% | 0.00% | 0.00% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 96.43% | 99.01% | 99.50% | 99.67% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | 0.00% | 0.00% | 25.00% | 20.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | -16059.09% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | -16136.36% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
